Search

Displaying results 2381 - 2390 of 7498 in total
  1. Drug

    gamma-Hydroxybutyric acid

    go.drugbank.com/drugs/DB01440
    ApprovedIllicitInvestigational

    It is currently regulated in the US and sold by Jazz Pharmaceuticals under the name Xyrem. However, it is important to note that GHB is a designated Orphan drug (in 1985).

    Synonyms: oxy-n-butyric acid
  2. Drug

    Imlunestrant

    go.drugbank.com/drugs/DB19043
    ApprovedInvestigational

    [L54046] Imlunestrant works by antagonizing ER transcriptional activity and, by forming an unstable drug-receptor complex, promotes ER degradation via the ubiquitin-proteasome pathway. … progression on at least one line of endocrine therapy.

  3. Drug

    Toremifene

    go.drugbank.com/drugs/DB00539
    ApprovedInvestigational

    [A256928] Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however … , it also has antiestrogenic (estrogen-antagonist) activity on breast tissue.

  4. Drug

    Trospium

    go.drugbank.com/drugs/DB00209
    ApprovedInvestigational

    [L6208] Trospium is manufactured by _Indevus Pharmaceutical Inc._ and was granted FDA approval in 2007.[L6211] … [L6208] An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination.

  5. Drug

    Prademagene zamikeracel

    go.drugbank.com/drugs/DB17895
    ApprovedInvestigational

    [L53008] Prademagene zamikeracel was first approved by the FDA on April 29, 2025, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a skin disorder associated with excessive blistering … [L53013] It was granted an Orphan Drug designation by the EMA.[A273833]

  6. Drug

    Etonogestrel

    go.drugbank.com/drugs/DB00294
    ApprovedInvestigational

    [A37184] The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001.[L5692]

  7. Drug

    Rurioctocog alfa pegol

    go.drugbank.com/drugs/DB16007
    ApprovedInvestigational

    [A245149] Hemophilia A is the most common inherited bleeding disorder leading to deficiency of factor VIII, which is caused by defects in the F8C gene that encodes coagulation factor VIII. … It was first approved by the European Commission in January 2018.

  8. Drug

    Trifluridine

    go.drugbank.com/drugs/DB00432
    ApprovedInvestigational

    Trifluridine is a fluorinated pyrimidine nucleoside that is structurally related to [idoxuridine] [A35271]. … It is an active antiviral agent in ophthalmic solutions used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus.

  9. Drug

    Dexbrompheniramine

    go.drugbank.com/drugs/DB00405
    Approved

    Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria.

    Synonyms: 3-(4-bromophenyl)- N,N-dimethyl- 3-pyridin-2-yl-propan-1-amineMixtures: Dologesic NF, WesTussin DM NF
  10. Drug

    Dordaviprone

    go.drugbank.com/drugs/DB14844
    ApprovedInvestigational

    On August 6, 2025, dordaviprone was granted accelerated approval by the FDA.[L53838] It is used to treat patients with diffuse midline glioma harboring an H3 K27M mutation.